Search results
Showing 31 to 45 of 69 results for cystic fibrosis
Monitoring for cystic-fibrosis-related diabetes:- What is the most effective strategy to detect diabetes in people with cystic...
Liver disease:- Should all children with meconium ileus receive ursodeoxycholic acid from diagnosis?
of mortality in people with cystic fibrosis, and around 10 to 30% of people with cystic fibrosis will develop...
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Antibiotics should not be issued as first line of treatment for a cough, says NICE and PHE
People should take honey or cough medicines instead but speak to their GP if it persists for longer than three weeks
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
Faltering growth: recognition and management of faltering growth in children (NG75)
This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Implementing transition care locally and nationally using the 'Ready Steady Go' programme
appointment using 'Go' from RSG compared to no structured transition (78% cf 54%). We anticipate this improving further. Starting RSG...
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)
Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation.
with idiopathic pulmonary fibrosis:- Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary...